Highlights and News

Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue - Nature

Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue  Nature

Deciphering the molecular landscape of rheumatoid arthritis offers new insights into the stratified treatment for the condition - Frontiers

Deciphering the molecular landscape of rheumatoid arthritis offers new insights into the stratified treatment for the condition  Frontiers

Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohorts - The Lancet

Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohorts  The Lancet

Clinical implications of synovial tissue phenotypes in rheumatoid arthritis - Frontiers

Clinical implications of synovial tissue phenotypes in rheumatoid arthritis  Frontiers

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial - Nature

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial  Nature

(PDF) Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - researchgate.net

(PDF) Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial  researchgate.net

Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials - The Lancet

Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials  The Lancet

Oral Presentation Abstracts - 2024 - International Journal of Rheumatic Diseases - Wiley Online Library

Oral Presentation Abstracts - 2024 - International Journal of Rheumatic Diseases  Wiley Online Library

Are innovation and new technologies in precision medicine paving a new era in patients centric care? - Journal of Translational Medicine

Are innovation and new technologies in precision medicine paving a new era in patients centric care?  Journal of Translational Medicine

Clinical Applications of Synovial Biopsy - Frontiers

Clinical Applications of Synovial Biopsy  Frontiers

Rheumatoid arthritis - The Lancet

Rheumatoid arthritis  The Lancet

Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics - Nature

Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics  Nature

Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy - Frontiers

Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy  Frontiers

Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial - The Lancet

Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial  The Lancet

Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis - Nature

Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis  Nature

Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis - Frontiers

Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis  Frontiers

Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis - Nature

Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis  Nature

Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes - Frontiers

Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes  Frontiers

A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients - Frontiers

A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients  Frontiers

Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs - Frontiers

Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs  Frontiers

Table 1 Identification of poor prognostic factors in randomized trials... - researchgate.net

Table 1 Identification of poor prognostic factors in randomized trials...  researchgate.net